Fresh off IPO, ‘biofacturing’ company Zymergen’s stock plunges about 70% after some really bad news Last Updated: Aug. 3, 2021 at 6:16 p.m. ET
Less than four months after going public, Zymergen announces that its sole current product is struggling, a major target market may not pan out, and the CEO is gone; more than two-thirds of $3 billion-plus valuation disappears.